SEC Filing Summary: Ra Medical Systems, Inc. (RMED)
Business Context and Reporting Period
This Form 8-K was filed by Ra Medical Systems, Inc. on June 2, 2023. The filing serves to announce the company's financial results for the three months ended March 31, 2023. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Fort Mill, SC. The company's common stock trades on the NYSE American under the symbol RMED.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the detailed financial results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the text of this 8-K.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed within the text of this filing. The document functions solely as a notification of the release of Q1 2023 results.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings unless expressly stated. No specific guidance, management commentary, risks, or unusual items are detailed in the body of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release) for actual Q1 2023 revenue, net loss, and cash position figures.
- Verify the company's status as an emerging growth company and any associated reporting exemptions.
- Confirm the trading status of RMED on the NYSE American.
- Note that the financial data in this 8-K is not legally "filed" and requires cross-referencing with the attached press release for official metrics.